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Familial glucocorticoid deficiency (FGD), or hereditary 
unresponsiveness to adrenocorticotropic hormone (ACTH),
is a rare autosomal recessive disease characterized by 
glucocorticoid deficiency in the absence of mineralocorticoid
deficiency. Mutations of the ACTH receptor, also known 
as the melanocortin-2 receptor (MC2R), account for
approximately 25% of FGD cases (1). More recently, 
Metherell et al (2) demonstrated that mutations in 
melanocortin-2 receptor accessory protein (MRAP), 
encoding a new interacting partner of the ACTH receptor,
caused FGD in 19 of 104 kindreds with confirmed FGD and
no ACTH receptor mutations, and they account for a further
15–20% of FGD cases.
In the current paper, we describe the first Turkish 
patient with FGD type 2 due to a known MRAP mutation.
Case Report
A male baby was referred to our clinic for evaluation of
hypoglycemic convulsions at the age of six months. He was
born to consanguineous parents after an uneventful 
pregnancy with a birth weight of 4750 g. Medical history 
revealed that he had had a convulsion on the first day of life
and had been receiving antiepileptic treatment since then.
While on antiepileptic treatment, he had convulsive 
episodes again on three different occasions. The etiology of
the convulsions had not been evaluated before. He was the
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and one female, had died on the first day of their lives. The
other three siblings, two males and a female, were 
reported to be healthy. The baby had a male cousin, who
was diagnosed as a case of isolated cortisol deficiency
(Figure 1). 
On physical examination, length was 73 cm (97th
percentile; SDS:+2), weight 8700 g (90th percentile;
SDS:+1.4), and head circumference was 46 cm (97th
percentile). Blood pressure was 90/60 mmHg. His mid-
parental target height was 167 cm (10th percentile, SDS:-1).
Examination of the external genitalia revealed a penis of
normal length and bilaterally palpable testes in the scrotum.
Hyperpigmentation of the skin was noted. There were no
signs of alacrima or achalasia. Other examination findings
were unremarkable. Blood chemistry results were: glucose: 
63 mg/dL, Na: 140 mmol/L, K: 4 mmol/L, Cl: 109 mmol/L,
ALT: 28 IU/mL, and AST: 30 IU/mL. Total blood count was
normal. Serum hormone analyses showed the following:
17-OH progesterone: 0.01 ng/mL (0.03-0.9), androstenedione:
0.01 ng/mL (<0.1-0.17), DHEA-S: 3 ng/mL (50-480), cortisol:
0.6 μg/dL (2.8-23), ACTH:708 pg/mL (6-48), plasma renin 
activity (PRA): 57 ng/mL/hr (2.35-37), aldosterone: 
801 pg/mL (50-900). The bone age, evaluated by X-ray of
the   left hand and wrist  according to the Greulich-Pyle 
atlas, was found to be equivalent to 9 months. Adrenal 
ultrasonography revealed that both adrenal glands were
small in size -left: 6x8 mm, and right: 7x8 mm in diameter.
Cranial ultrasonography was normal. Based on these 
findings, a diagnosis of isolated glucocorticoid deficiency
was made, and oral hydrocortisone treatment at a dose of
10 mg/m2/d was started. 
For the molecular diagnosis, the entire coding region of
the NR0B1 (DAX1), the MC2R gene and the 6 exons of the
MRAP gene were amplified by PCR with intronic primers,
and the PCR products on both the sense and antisense
strand were sequenced. No mutation was found in 
the NR0B1 and MC2R genes. We found a homozygous 
deletion of one nucleotide at the canonical 5α donor splice
site (c.106+1delG) in intron 3 of MRAP gene. The mutation was
confirmed with a second independent PCR and  sequence 
reaction. The mother was found to be a heterozygous carrier
for the 1-bp deletion in intron 3. 
On his most recent visit, at the age of four years and
eight months, the patient had no hyperpigmentation. His 
height was 103 cm (25th percentile), weight 17 kg (25th
percentile), testis volumes bilaterally were 2 ml with a 
penile length of 5 cm. The bone age was evaluated as 
4 years.  His neurodevelopment was appropriate for age.
The ACTH level was suppressed to slightly above the 
normal limit (53 pg/ml)  by 20 mg/m2/d oral hydrocortisone
treatment. 
An informed consent for publication was taken from the
mother.
Discussion
FGD is a rare autosomal recessive disorder characterized
by isolated glucocorticoid deficiency in the absence of 
mineralocorticoid deficiency. These patients have low cortisol
and high ACTH levels with a normal renin-aldosterone axis.
FGD usually presents in infancy or in early childhood with
hyperpigmentation, failure to thrive, recurrent infections,
hypoglycemic attacks and convulsions that may result in 
coma or death (3). 
The differential diagnosis of adrenal insufficiency in 
infancy includes congenital disorders such as congenital 
adrenal hyperplasia, adrenal hypoplasia, adrenoleukodystrophy
(ALD), ACTH resistance syndromes (FGD, Allgrove syndrome)
and Kearns-Sayre syndrome; and acquired conditions such as 
adrenal hemorrhage, trauma and infections (4,5). 
Congenital adrenal hyperplasia was excluded by hormone
analysis; acquired causes of adrenal insufficiency were 
also excluded by history and laboratory findings. Allgrove
syndrome was not considered because of the absence of
alacrima or achalasia. ACTH receptor gene sequences were
normal in our patient excluding FGD type 1. Congenital 
adrenal hypoplasia was also unlikely, because he had 
well-developed genitalia and no mutation of the DAX1 gene. 
Mutations of ACTH receptor (MC2R) account for about
25% of FGD cases (FGD type 1, OMIM 202200) (1). 
Recently, mutations in MRAP gene, a gene encoding a small
single transmembrane domain protein known as MRAP,  
have been described in a group of patients with ACTH 
resistance syndrome but with no mutations in MC2R gene
(FGD type 2, OMIM 607398). MRAP, located at 21q22.1, is
an essential cofactor for MC2R expression in certain cell
types and seems to have a role in the processing, trafficking,
or function of MC2R (2). MRAP has two isoforms, namely,
MRAPα and MRAPβ which differentially regulate the function
of MC2R (6), and  so far 9 different mutations of MRAP in
FGD patients have been described; they all result in either
an absent or significantly truncated protein of both 
isoforms (7). MRAP mutations comprise approximately
20% of patients with FGD (2). In our patient, we found a 
1-bp deletion at the canonical 5α donor splice site
(c.106+1delG) in intron 3 of MRAP gene in the DNA of the
patient in a homozygous state. His mother was heterozygous
for the 1-bp deletion. In their study, Metherell et al (2) identified
the 1-bp deletion, c. 106+1delG, in 6 individuals from 5 
families with glucocorticoid deficiency, making this the 
second frequent mutation causing FGD unrelated to 
defects in the MC2R gene. To our current knowledge, 1-bp
deletion (c. 106+1delG) in intron 3 of MRAP gene, identified
in the DNA of the patient, can be regarded as the cause of
FGD type 2.
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patients from Turkey, Berberoglu et al (8) reported 5 patients
with FGD type 1. In this series, three siblings had homozygous
V 142 L mutations and the other two siblings had homozygous
D103N mutations in MC2R gene. To our knowledge, our 
patient is the first reported Turkish patient with FGD type 2,
with a known MRAP mutation. The patient was the 
offspring of consanguineous parents and his four siblings
had died in the neonatal period, probably due to 
glucocorticoid insufficiency. 
The long-term neurological consequences of FGD 
depend on the severity and number of hypoglycemic 
episodes during childhood. Modan-Moses et al (9) reported
an Ethiopian infant, who presented with psychomotor 
retardation, spastic quadriparesis and microcephaly due to
severe hypoglycemic attacks. They speculated that this
phenotype could result from a novel MRAP mutation. 
Our patient was diagnosed with FGD at the age of six
months and had four convulsion episodes until presentation.
Despite this history of several hypoglycemic attacks, at his
most recent visit at age of four years and eight months, the
patient’s neurodevelopment was appropriate for age.
Patients with FGD often have undetectable levels of 
adrenal androgens (10). In our patient also, 17-OH 
progesterone, androstenedione and DHEA-S levels were
very low. 
Tall stature is observed in some FGD type 1 cases 
with MC2R mutations (11). Bone age was reported to be
advanced in some of these patients, a finding, which was
more pronounced before the initiation of treatment. It is 
reported that hydrocortisone replacement may decrease
the height growth. Nevertheless, these children become tall
adults (12). The excessive growth has been proposed to be
due to high plasma ACTH levels (13). A possible mechanism
for excessive growth is that all five melanocortin receptors
are present in bone, and ACTH can stimulate cAMP 
production and gene expression in bone cells (11,14). 
Unlike FGD type1, FGD type 2 patients are known to be
of normal height. At presentation, our patient’s length, 
weight, and head circumference percentiles were all above
the parental target. Bone age was also advanced by three
months. Although length in infancy may not reflect final 
height, we suggest that increased ACTH or related 
pathophysiologic changes might have caused advanced
growth in this patient. After the initiation of treatment, 
anthropometric percentiles gradually decreased and came
down to 25th percentile at age four years and eight months.
On the most recent visit, it was observed that the bone 
age was delayed by about 8 months. The patient will be
monitored closely for the effects of possible overdose of
treatment.
FGD is characterized by isolated glucocorticoid deficiency
in the presence of a normal renin-aldosterone axis. However,
mild derangement of the renin-angiotensin system and mild
salt-wasting at the time of diagnosis have been reported in
some cases (12,15). In our patient, the initial PRA was also
moderately elevated despite normal serum electrolyte levels.
However, PRA and aldosterone levels on follow-up have 
remained within normal ranges. In these patients, definitive
diagnosis can be made by finding mutations in the MC2R 
or recently described MRAP gene. Nevertheless, in about
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Figure 1. Family pedigree showing the relationship of the patient to the affected cousin and also to the unexplained neonatal deaths in his 
siblings and relatives.
55-60% of the FGD cases, the gene defect causing the 
disease has remained unidentified. 
In conclusion, clinical awareness of this condition is of
considerable prognostic and therapeutic significance. 
Further studies describing new cases and mutations 
causing FGD will contribute to understanding the 
mechanism of this rare and potentially life-threatening 
disease.
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